IgG4-related disease: why high IgG4 and fibrosis?
© BioMed Central Ltd 2013
Published: 25 January 2013
The hallmarks of IgG4-related disease (IgG4-RD) are lymphoplasmacytic tissue infiltration with a predominance of IgG4-positive plasma cells, accompanied by fibrosis, obliterative phlebitis, dacryoadenitis, and elevated levels of IgG4. In a recent issue of Arthritis Research & Therapy, Tsuboi and colleagues demonstrated that regulatory T (Treg) cell-and T helper 2 (Th2) cell-derived cytokines contribute to the pathogenesis of Mikulicz's disease, an activation pathway that appears to be common for IgG4-RD. Additional organ-specific factors may account for the different organ involvement of IgG4-RD.
IgG4-related disease (IgG4-RD) is a newly categorized disease entity initially recognized in Japan but increasingly also in other parts of the world [1, 2]. Most often the diagnosis is made in patients with autoimmune pancreatitis. Additional presentations include patients with lacrimal and salivary gland involvement, formerly Mikulicz's disease (MD), which was once thought to be a subset of Sjögren's syndrome (SS).
The hallmarks of IgG4-RD are lymphoplasmacytic tissue infiltration with a dominance of IgG4-positive plasma cells, accompanied by fibrosis, obliterative phlebitis, dacryoadenitis, and elevated levels of IgG4. The pathogenesis of IgG4-RD is poorly understood; findings consistent with both an autoimmune disorder and an allergic disorder are present [1, 2].
IgG4 production is controlled primarily by T helper 2 (Th2) cells [3, 4]. Th2 cytokines interleukin-4 (IL-4) and IL-13 enhance the production of IgG4 and IgE. In contrast, IL-10, IL-12, and IL-21 shift the balance between IgG4 and IgE, favoring IgG4. In the Th2 cytokine-driven immune reaction, IgG4 production is induced preferentially by the activation of IL-10 produced by regulatory T (Treg) cells . Thus, selective IgG4 induction is referred to as the combined effect of Th2 and Treg cells.
Very recently, Tanaka and colleagues  examined the Th1, Th2, and Treg cytokine expression in LSGs from patients with IgG4-RD and SS. The authors showed that the levels of mRNA for both Th2 and Treg cytokines were significantly higher in LSGs from patients with IgG4-RD (MD) but that the expressions of Th1 and Th2 cytokines were higher in LSGs from patients with SS. The upregulation of Treg cytokines is identical to the findings reported by Tsuboi and colleagues , indicating that Treg cells play an important role in the pathogenesis of IgG4-RD (MD). In contrast, Tsuboi and colleagues showed that Th2 cytokines such as IL-4 and IL-13 were not significantly overexpressed in LSGs from patients with IgG4-RD (MD) but were increased if compared with those in healthy subjects. This finding supports the notion that Th2 cytokines such as IL-4 and IL-13 play a common B cell-activating role in both IgG4-RD (MD) and SS. Contrary to Th2 and Treg cytokines, Th1 cytokines were upregulated only in LSGs from patients with SS , suggesting that Th1 cells function as key players in the pathogenesis of SS.
Consistent with the findings in MD, analyses of the expression of cytokines in inflammatory lesions from patients with IgG4-related sclerosing pancreatitis and cholangitis  or tubulointerstitial nephritis  showed that tissue mRNA expression of Th2 (IL-4) and Treg cytokines (IL-10 and TGF-β) was substantially higher than in other diseases. Many mononuclear cells expressing IL-4 or IL-10 were identifiable in affected organs by in situ hybridization . Moreover, circulating CD4+CD25+Treg cells were significantly increased in PBMCs from patients with autoimmune pancreatitis .
Further examinations should shed light on the molecular mechanisms controlling the activation of this pathway.
activation-induced cytidine deaminase
a proliferation-inducing ligand
B cell-activating factor
interferon regulatory factor 4
labial salivary gland
peripheral blood mononuclear cell
transforming growth factor-beta
- Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, Matsui S, Sumida T, Mimori T, Tanaka Y, Tsubota K, Yoshino T, Kawa S, Suzuki R, Takegami T, Tomosugi N, Kurose N, Ishigaki Y, Azumi A, Kojima M, Nakamura S, Inoue D: A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol. 2012, 22: 1-14. 10.1007/s10165-011-0508-6.PubMed CentralView ArticlePubMed
- Stone JS, Yoh Z, Vikram D: IgG4-related disease. N Engl J Med. 2012, 366: 539-551. 10.1056/NEJMra1104650.View ArticlePubMed
- Aalverse RC, Stapel SO, Schuurman J, Rispens T: Immunoglobulin G4: an odd antibody. Clin Exp Allergy. 2009, 39: 469-477. 10.1111/j.1365-2222.2009.03207.x.View Article
- Nirula A, Glaser SM, Kalled SL, Taylar FR: What is IgG4? A review of the biology of a unique immunoglobulin subtype. Curr Opin Rheumatol. 2011, 23: 119-124. 10.1097/BOR.0b013e3283412fd4.View ArticlePubMed
- Tsuboi H, Matsuo N, Iizuka M, Tsuzuki S, Kondo Y, Tanaka A, Moriyama M, Matsumoto I, Nakamura S, Sumida T: Analysis of IgG4 class switch-related molecules in IgG4-related disease. Arthritis Res Ther. 2012, 14: R171-10.1186/ar3924.PubMed CentralView ArticlePubMed
- Tanaka A, Moriyama M, Nakashima H, Miyake K, Hayashida JN, Maehara T, Shinozaki S, Kubo Y, Nakamura S: Th2 and regulatory immune reactions contributes to IgG4 production and the initiation of Mikulicz's disease. Arthritis Rheum. 2012, 64: 254-263. 10.1002/art.33320.View ArticlePubMed
- Zen Y, Fujii T, Harada K, Kawano M, Yamada K, Takahira M, Nakanuma Y: Th2 and regulatory immune reaction are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Hepatology. 2007, 45: 1538-1546. 10.1002/hep.21697.View ArticlePubMed
- Nakashima H, Miyake K, Moriyama M, Tanaka A, Watanabe M, Abe Y, Sato H, Nakamura S, Saito T: An amplification of IL-10 and TGF-beta in patients with IgG4-related tubulointerstitial nephritis. Clin Nephrol. 2010, 73: 385-391.View ArticlePubMed
- Miyoshi H, Uchida K, Taniguchi T, Yazumi S, Matsushita M, Takaoka M, Okazaki K: Circulating naïve and CD4+CD25high regulatory T cells in patients with autoimmune pancreatitis. Pancreas. 2008, 36: 133-140. 10.1097/MPA.0b013e3181577553.View ArticlePubMed